Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2007 December;73(12) > Minerva Anestesiologica 2007 December;73(12):647-50

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ANESTESIOLOGICA

A Journal on Anesthesiology, Resuscitation, Analgesia and Intensive Care


Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,036


eTOC

 

REVIEW ARTICLES  


Minerva Anestesiologica 2007 December;73(12):647-50

language: English

My brother has severe sepsis – Should he receive Xigris®?

Suter P. M.

University of Geneva, Switzerland


FULL TEXT  


Six years ago, a publication in a quite well known scientific medical journal brought hope and a good dose of optimism to sepsis therapy and the critical care community. For the first time, a careful randomized controlled trial in patients with severe sepsis or septic shock seemed to show a clearly beneficial effect of a new drug, i.e. of activated recombinant human protein C. This new treatment possibility was welcomed as an important breakthrough and a hope for a better management of a deadly disease. However, further evaluation of the results of the trial and new investigations did not confirm entirely the initial optimism. As a consequence, the adequate indications for this expensive drug remain controversial.

top of page

Publication History

Cite this article as

Corresponding author e-mail